A5079001491- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- Galectins and Cancer Biology
- T-cell and B-cell Immunology
- Immune cells in cancer
International Centre for Genetic Engineering and Biotechnology
2024
Abstract Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 potential DC-based therapies tumors carrying varied levels bona-fide neoantigens (neoAgs) remain unclear. Here we develop a hypermutated non-small lung cancer female mice, encoding genuine MHC-I neoepitopes study neoAgs-specific spontaneous settings upon Flt3L + αCD40 (DC-therapy). We find...
Receptors controlling the cross-presentation of tumor antigens by macrophage subsets in cancer tissues are poorly explored. Here, we show that TIM4
Conventional type 1 dendritic cells (cDC1) are critical regulators of anti-tumoral T-cell responses. The structure and abundance intercellular contacts between cDC1 CD8 T in cancer tissues is important to determine the outcome response. However, molecular determinants controlling stability cDC1–CD8 interactions during progression remain poorly investigated. Here, we generated a genetic model non-small cell lung crossed fluorescent reporter (KP-XCR1venus) allow detection cDC1-CD8T clusters...
Abstract The efficacy of immune checkpoint blockade (ICB) in NSCLC depends on the tumor mutational burden (TMB). However, a fraction patients with high TMB and predicted immunogenic neoantigens (neoAgs) do not respond. Here we show that model highly mutated NSCLC, cross-presenting cDC1s are required to induce broad effector CD8+ T cell responses both strong weak endogenous neoAgs. Importantly, cDC1 amplification by Flt3L increases immunogenicity MHC class-I neoepitopes promotes regression,...